1. Home
  2. BBIO vs OMF Comparison

BBIO vs OMF Comparison

Compare BBIO & OMF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BBIO
  • OMF
  • Stock Information
  • Founded
  • BBIO 2015
  • OMF 1920
  • Country
  • BBIO United States
  • OMF United States
  • Employees
  • BBIO N/A
  • OMF N/A
  • Industry
  • BBIO Biotechnology: Pharmaceutical Preparations
  • OMF Finance: Consumer Services
  • Sector
  • BBIO Health Care
  • OMF Finance
  • Exchange
  • BBIO Nasdaq
  • OMF Nasdaq
  • Market Cap
  • BBIO 6.7B
  • OMF 5.9B
  • IPO Year
  • BBIO 2019
  • OMF 2013
  • Fundamental
  • Price
  • BBIO $34.57
  • OMF $48.90
  • Analyst Decision
  • BBIO Strong Buy
  • OMF Buy
  • Analyst Count
  • BBIO 12
  • OMF 13
  • Target Price
  • BBIO $52.64
  • OMF $58.33
  • AVG Volume (30 Days)
  • BBIO 2.7M
  • OMF 1.3M
  • Earning Date
  • BBIO 05-01-2025
  • OMF 04-29-2025
  • Dividend Yield
  • BBIO N/A
  • OMF 8.51%
  • EPS Growth
  • BBIO N/A
  • OMF N/A
  • EPS
  • BBIO N/A
  • OMF 4.24
  • Revenue
  • BBIO $221,902,000.00
  • OMF $2,497,000,000.00
  • Revenue This Year
  • BBIO $12.42
  • OMF $71.33
  • Revenue Next Year
  • BBIO $123.19
  • OMF $9.19
  • P/E Ratio
  • BBIO N/A
  • OMF $11.53
  • Revenue Growth
  • BBIO 2285.27
  • OMF N/A
  • 52 Week Low
  • BBIO $21.62
  • OMF $41.70
  • 52 Week High
  • BBIO $39.47
  • OMF $58.90
  • Technical
  • Relative Strength Index (RSI)
  • BBIO 51.35
  • OMF 43.47
  • Support Level
  • BBIO $35.77
  • OMF $48.20
  • Resistance Level
  • BBIO $37.06
  • OMF $53.43
  • Average True Range (ATR)
  • BBIO 1.40
  • OMF 1.78
  • MACD
  • BBIO 0.18
  • OMF 0.25
  • Stochastic Oscillator
  • BBIO 47.67
  • OMF 45.94

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

About OMF OneMain Holdings Inc.

OneMain Holdings Inc is engaged in nonprime consumer finance companies in the United States and is one of only a few companies in the consumer installment lending industry. It formed after a transaction brought together two branch-based consumer finance companies with complementary strategies and locations. Its services include providing personal loan products, offering credit and noncredit insurance, servicing loans, pursuing strategic acquisitions and dispositions of assets and businesses, and on occasion, establishing joint ventures or forming strategic alliances. The company's one reportable segment is consumer and insurance. In addition to hundreds of branches, the company also has an online business. The main source of revenue is net interest income.

Share on Social Networks: